CytomX Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO CytomX Therapeutics is Sean McCarthy, benoemd in Aug2011, heeft een ambtstermijn van 13.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.61M, bestaande uit 25% salaris en 75% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.71% van de aandelen van het bedrijf, ter waarde $ 481.61K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 4.8 jaar.
Belangrijke informatie
Sean McCarthy
Algemeen directeur
US$2.6m
Totale compensatie
| Percentage CEO-salaris | 25.0% |
| Dienstverband CEO | 13.3yrs |
| Eigendom CEO | 0.7% |
| Management gemiddelde ambtstermijn | 3.6yrs |
| Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
Oct 26
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$14m |
| Jun 30 2024 | n/a | n/a | US$11m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
Compensatie versus markt: De totale vergoeding ($USD 2.61M ) Sean } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).
Compensatie versus inkomsten: De vergoeding van Sean is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sean McCarthy (57 yo)
13.3yrs
Tenure
US$2,611,138
Compensatie
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 13.3yrs | US$2.61m | 0.71% $ 481.6k | |
| Senior VP & Chief Scientific Officer | 1.8yrs | US$1.21m | 0.085% $ 57.8k | |
| Senior VP | 3.6yrs | US$1.05m | 0.079% $ 53.9k | |
| Chief Financial Officer | 2.2yrs | geen gegevens | 0.039% $ 26.3k | |
| Senior VP | 6.5yrs | US$1.21m | 0.10% $ 67.8k | |
| Senior VP & Chief Human Resources Officer | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Intellectual Property | 5.8yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Quality & Product Manufacturing | 1.8yrs | geen gegevens | geen gegevens | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | geen gegevens |
3.6yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CTMX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 13.3yrs | US$2.61m | 0.71% $ 481.6k | |
| Independent Director | 5.5yrs | US$75.12k | 0.0066% $ 4.5k | |
| Member of Scientific Advisory Board | 4.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.9yrs | US$78.62k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$77.12k | 0% $ 0 | |
| Lead Independent Director | 9.2yrs | US$105.12k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.9yrs | US$8.03m | geen gegevens | |
| Independent Director | 3.2yrs | US$69.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 1.8yrs | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CTMX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).